$275.33+3.3%Nov 13 close
Figures through September 30, 2026, from the 6-K filed November 12, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $408.5M | $236.1M | +73.03% |
| Profit per share | $1.19 | -$1.11 | +208.00% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
The quote and the company description come from the 6-K Ascendis Pharma A/S filed on November 12, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Ascendis Pharma A/S reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.